**Name of Journal:** *World Journal of Gastrointestinal Endoscopy*

**Manuscript NO:** 45196

**Manuscript Type:** REVIEW

**Role of endoscopy in acute gastrointestinal bleeding in real clinical practice: An evidence-based review**

Jung K *et al*. Role of endoscopy in acute gastrointestinal bleeding

Kyoungwon Jung, Won Moon

**Kyoungwon Jung, Won Moon,** Department of Internal Medicine, Kosin University College of Medicine, Busan 49267, South Korea

**ORCID number:** Kyoungwon Jung (0000-0002-5324-7803); Won Moon (0000-0002-3963-8680).

**Author contributions:** Moon W substantially contributed to the conception and design of the review; Jung K contributed to the acquisition of data and drafting the article.

**Conflict-of-interest statement:** The authors declare that they have no conflict of interests.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Corresponding author:** **Won Moon, MD, PhD, Professor,** Department of Internal Medicine, Kosin University College of Medicine, 262 Gamcheon-ro, Seo-gu, Busan 49267, South Korea. moonone70@hanmail.net

**Telephone**: +82-51-9906103

**Fax**: +82-51-9905055

**Received:** December 17, 2018

**Peer-review started:** December 17, 2018

**First decision:** January 6, 2019

**Revised:** February 2, 2019

**Accepted:** February 13, 2019

**Article in press:**

**Published online:**

**Abstract**

Although upper gastrointestinal bleeding is usually segregated from lower gastrointestinal bleeding, and guidelines for gastrointestinal bleeding are divided into two separate sections, they may not be distinguished from each other in clinical practice. Most patients are first observed with signs of bleeding such as hematemesis, melena, and hematochezia. When a patient with these symptoms presents to the emergency room, endoscopic diagnosis and treatment are considered together with appropriate initial resuscitation. Especially, in cases of variceal bleeding, it is important for the prognosis that the endoscopy is performed immediately after the patient stabilizes. In cases of suspected lower gastrointestinal bleeding, full colonoscopy after bowel preparation is effective in distinguishing the cause of the bleeding and treating with hemostasis. The therapeutic aspect of endoscopy, using the mechanical method alone or injection with a certain modality rather than injection alone, can increase the success rate of bleeding control. Therefore, it is important to consider the origin of bleeding and how to approach it. In this article, we aim to review the role of endoscopy in diagnosis, treatment, and prognosis in patients with acute gastrointestinal bleeding in a real clinical setting.

**Key words:** Endoscopy; Gastrointestinal bleeding; Endoscopic bleeding control; Emergency bowel preparation; Bedside endoscopy; Second-look endoscopy

© **The Author(s) 2019**. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** When a patient with signs of bleeding, such as hematemesis, melena, and hematochezia, presents to the emergency room, an endoscopic approach is considered together with initial resuscitation. Timely endoscopy and appropriate bowel preparation are very important in patients with acute gastrointestinal bleeding. In addition, mechanical bleeding control is an imperative part of therapeutic endoscopy. After bleeding control, the risk classification of rebleeding is important because old age, concomitant diseases, and use of drugs (non-steroidal anti-inflammatory drug, antiplatelet, and anticoagulant drugs) are increasing. Therefore, endoscopy has a very important role in the diagnosis, therapy, and prognosis of gastrointestinal bleeding.

Jung K, Moon W. Role of endoscopy in acute gastrointestinal bleeding in real clinical practice: An evidence-based review. *World J Gastrointest Endosc* 2019; In press

**INTRODUCTION**

Along with abdominal pain, gastrointestinal bleeding (GIB) is one of the most common conditions in the emergency department. Upper GIB (UGIB) is a major problem that has been declining over the past 20 years but still has a mortality rate of 2.1%[1]. Lower GIB (LGIB) has a mortality rate less than 5%, but it is common in older patients and those with intestinal ischemia and comorbidity[2].

GIB usually manifests as hematemesis (vomiting of blood or coffee-ground-like material), melena (black or tarry stools), and hematochezia. UGIB appears as hematemesis in 40%-50%, and as melena or hematochezia in 90%-98%, especially hematochezia in massive UGIB[3]. However, patients with LGIB typically present with hematochezia, but right-sided colonic bleeding or small bowel bleeding may show as melena[4]. Therefore, it is frequently difficult to distinguish between UGIB and LGIB based on only the initial symptoms of the patient[5]. In real clinical practice, it is necessary to approach the patient with melena and hematochezia based on the main symptom rather than UGIB or LGIB.

Early resuscitation of acute GIB is usually performed by the physician in the emergency room, but highly skilled endoscopists are needed to determine the cause and location of bleeding. In many cases, endoscopic treatment should be performed to stop bleeding and prevent recurrence[6]. Here, we will review the diagnostic, therapeutic, and prognostic roles of endoscopy in patients with clinical signs and symptoms of GIB.

**ROLE OF ENDOSCOPY IN THE DIAGNOSTIC APPROACH**

***Timing of upper endoscopy for patients with hematemesis or melena***

There is still a debate as to when endoscopy should be undertaken in patients with suspicious acute GIB. In particular, it is difficult to clearly distinguish the cause of upper gastrointestinal bleeding from clinical symptoms alone. The causes of upper gastrointestinal bleeding were summarized by frequency in Table 1.

When variceal bleeding is strongly suspected, endoscopy should be performed just after proper resuscitation when the patient is hemodynamically stable[7]. The guidelines of American Association for the Study of Liver Diseases recommend that endoscopy should be performed within 12 h for acute variceal bleeding[8]. Because gastroesophageal varix can be observed in more than 50% of patients with liver cirrhosis, and the 6-wk mortality of varix bleeding is about 20%, urgent endoscopy should be considered in patients with hematemesis and liver cirrhosis[7,9].

In the case of non-variceal UGIB, a previous Asia-Pacific Working Group consensus recommended endoscopic intervention be taken within 24 h of onset of bleeding in patients at high risk of pre-endoscopic assessment (*e.g.*, Glasgow-Blatchford Score (GBS) ≥ 12; The GBS is a composite score of blood urea, hemoglobin, systolic blood pressure, pulse, history, and comorbidities)[10]. This consensus is similar to a recent cascade guideline of European Society of Gastrointestinal Endoscopy in 2018, which reported that endoscopy should be performed within 24 h after adequate initial management[11]. Therefore, it has been pointed out that, in patients who are hemodynamically unstable and presenting with massive hematemesis, endoscopy should not be done until after the patient is stabilized by resuscitation[12].

Several studies have investigated the role of emergency endoscopy within 12 h in non-variceal UGIB. A retrospective study of 361 patients found that patients undergoing emergency endoscopy had a 5-fold increase in the risk of adverse events including death, rebleeding, surgery, radiological intervention, or repeated endoscopic management. In a subgroup analysis of that study, time to endoscopy was not significant as a predictor of worse outcome and was a weaker prognostic factor in patients with a high GBS score (≥ 12 points) than in patients with a low score[13]. High-risk patients are more likely to undergo fluid therapy and rapid proton pump inhibitor (PPI) therapy before endoscopy because initial bleeding symptoms are more severe. This emergency medical therapy may be the most important factor to prevent a poor outcome from UGIB regardless of time of endoscopy.

A nation-wide cohort study by Laursen *et al*[14], which included 12601 peptic ulcer patients, suggested that patients with an American Society of Anesthesiology score of 3-5 points or who were hemodynamically unstable had a reduced rate of hospital mortality if they received an endoscopic intervention within 6-24 h after admission[14]. However, the exact timing within the 24 h is not yet clear. Another national survey conducted in the United Kingdom, which included 4478 patients, suggested an early endoscopy of fewer than 12 h after admission and, compared to endoscopy provided within 24 h, showed no association with lower mortality rate or need for surgery[15]. According to a cohort study in Singapore, the timing of endoscopy in high-risk UGIB patients with GBS > 12 is the most important factor related to all-cause mortality in hospitals[16]. The cut-off time of endoscopy that improved the survival rate was within 13 h from the onset of symptoms. Active hemorrhagic lesions requiring endoscopic hemostasis were frequent in patients who received endoscopy within 6 h, but it did not help in prevention of rebleeding, mortality, transfusion rate, or duration of hospitalization. Therefore, emergency endoscopy is not required within 6 h for all non-variceal UGIB.

In summary, recent guidelines and recent studies suggest that emergency endoscopy should be performed within 12 h if variceal bleeding is present or the patient is hemodynamically unstable[17]. In addition, endoscopy should be preceded by appropriate and prompt medical therapy, which includes fluid therapy and intravenous PPIs.

***What is the best option for patients with hematochezia: Sigmoidoscopy or colonoscopy***

Unlike UGIB, which is mostly divided into variceal bleeding and non-variceal bleeding, the causes of LGIB are variable, involving various clinical manifestations. Table 2 summarizes the causes of LGIB by category. Therefore, what should be done for patients with hematochezia? In cases of hemodynamic instability, emergency upper endoscopy should be considered while performing initial resuscitation because of the possibility of UGIB as mentioned above. However, if vital signs are stable, LGIB should be considered first.

In patients with hematochezia who are less than 50 years of age, anorectal disease predominates in about 90%, whereas the prevalence of colorectal cancer increases with age. Some researchers believe that total colonoscopy is not necessary for patients with hematochezia at age 50 or younger, and sigmoidoscopy alone is sufficient[18]. On the other hand, some authors suggest that colonoscopy be performed in all patients with hematochezia because it can help to diagnose associated diseases such as colorectal cancer and polyps[19]. In addition, patients who have undergone sigmoidoscopy might believe that full colonoscopy will reveal more dangerous and fatal diseases such as cancer. However, full colonoscopy can be required complete preparation and long observation time with pain. In some situations, anesthetics and long-term hospitalization are necessary[20].

Currently, there is no clear consensus on whether patients with hematochezia should undergo full colonoscopy or sigmoidoscopy alone. To summarize the opinions of several researchers, sigmoidoscopy without bowel preparation can be performed to rule out bleeding from anorectal disease. However, to investigate the combined presence of colon polyp or cancer, we suggest that full colonoscopy be performed for the entire colon investigation, regardless of the presence of bleeding and the success or failure of hemostasis in the anorectal area.

***In patients with suspected lower gastrointestinal bleeding, when is the best time to perform endoscopy?***

The optimal timing of colonoscopy for acute LGIB is controversial. Three recent systematic reviews with meta-analysis have attempted to address the question of whether urgent colonoscopy improves the outcome of LGIB. Seth *et al*[21] evaluated six studies including two randomized controlled trials (RCTs) and four observational studies involving 23419 patients who received urgent or elective colonoscopy. Urgent colonoscopy is one that is performed within 8 to 24 h of observing LGIB. The use of urgent colonoscopy increased the detection rate of stigmata for recent bleeding but did not reduce rebleeding, mortality, or surgical necessity[21]. Kouanda *et al*[22] evaluated 10172 patients with urgent colonoscopy and 14224 patients with elective colonoscopy in an analysis of 12 studies. Urgent colonoscopy was associated with increased use of endoscopic therapeutic intervention. The reason for the difference in the use of endoscopic therapy is that hemorrhoid band ligation was included as an intervention. However, there was no significant difference in localization of bleeding source, adverse event rates, rebleeding rates, transfusion requirement, or mortality. Moreover, a limitation was that the definition of urgent colonoscopy varies widely in every study from within 8 h to within 24 h[22]. The third meta-analysis was performed by Sengupta *et al*[23] and involved 422 patients in the early colonoscopy group (< 24 h) and 479 patients in the delayed colonoscopy group (>24 h). There was no statistically significant difference in blood transfusion requirement, need for surgery, or in-hospital mortality. Early colonoscopy showed a high correlation with detection rate of definite bleeding focus and endoscopic intervention[23].

The efficacy of early colonoscopy for reducing hospitalization, transfusion, and need for surgery is not clear. A timely colonoscopy is basically recommended as an initial diagnostic procedure for patients with acute LGIB because most guideline colonoscopy is highly accurate in detecting and treating the major causes of LGIB[4].

***Is bowel preparation helpful before colonoscopy?***

Bowel preparation is closely related to timing of colonoscopy. In urgent colonoscopy, there is no time to perform proper bowel preparation. However, if vital signs in patients with hematochezia suggest a low probability of UGIB, bowel preparation is recommended. Proper bowel preparation is associated with successful and safe colonoscopy insertion and the ability to detect and treat lesions and to prevent rebleeding of high-risk lesions such as diverticular bleeding or angiodysplastic bleeding[4]. Generally, urgent colonoscopy of acute LGIB is done with “rapid purge” bowel preparation of a high-dose (4-6 L) polyethylene glycol (PEG) formulation administered over 3 to 4 h[4,24]. Stools should be checked frequently during preparation, and PEG should be provided until the patient is properly prepared. To facilitate rapid purge[25], a nasogastric tube for PEG administration could be used for patients with low risk of aspiration[4].

Prospective trials evaluating urgent colonoscopy with PEG preparations appear to achieve adequate visualization of approximately 90% of the colon with 4-6 L of PEG over 3-4 h. In an RCT by Laine *et al*[26], the patients received 4 L of PEG solution over 3 h for urgent colonoscopy within 12 h of presentation, and no colonic preparation quality was reported; only 7% of patients required repeat colonoscopy because of inappropriate preparation. Another RCT by Green *et al*[27] reported only 8% of poor preparation cases in an urgent colonoscopy group using a similar preparation method. Because of the good efficacy of the urgent colonoscopy preparation method, the American College of Gastroenterology recommends not performing non-prepared colonoscopy in patients with acute LGIB[4]. Repaka *et al*[28] assessed the possibility of unprepared hydroflush colonoscopy in patients with severe LGIB. Only 13 procedures were included in the study, and the patients were treated with tap water enema and immediate colonoscopy without oral bowel preparation. The rate of cecal intubation was as low as 69.2%. A definite source of bleeding was found in only 38.5% of the patients, and 25% of the patients had repeated bleeding during the same hospitalization[28].

Although there are not many studies on the safety of bowel preparation in acute LGIB patients, overall bowel preparation is considered safe. Niikura *et al*[29] evaluated the safety of preparation and performance of colonoscopy in 161 patients admitted with acute LGIB compared to controls without bleeding. There was no significant difference in adverse events between the bleeding group and control group. None of the patients had volume overload, aspiration pneumonia, or loss of mental status[29]. In the guideline of the American College of Gastroenterology, precaution for aspiration is recommended for patients of old age and debilitation[4].

***Approach to unknown origin gastrointestinal bleeding***

Obscure GI bleeding (OBGIB) is defined as persistent or recurrent bleeding, despite of examination by esophagogastroduodenoscopy or colonoscopy[30]. OBGIB can be divided into overt bleeding with apparent gastrointestinal hemorrhage, such as hematochezia or melena, and occult bleeding, with repeated positive findings of fecal occult blood test or laboratory finding of iron deficiency anemia[30]. This OBGIB accounts for about 5% of all gastrointestinal bleeding, and it is known that more than 80% of these bleeding occur in the small intestine[31]. The development of capsule endoscopy has enabled the full examination of small intestine mucosa. The device-assisted enteroscopy has enabled therapeutic endoscopy for these lesions[32]. Details of small bowel bleeding are not covered in this review, but only the common causes of small bowel bleeding are summarized in the Table 2.

***Is it helpful to perform video capsule endoscopy in the emergency room?***

The first attempt to use video capsule endoscopy (VCE) in evaluating UGIB patients was performed in a multicenter study after nasogastric tube and conventional endoscopy[33]. Although bloody materials were detected significantly more often by VCE than by nasogastric tube aspiration, there was no difference in the identification of inflammatory lesions between VCE and sequential conventional endoscopy. VCE may be feasible and safe method in patients with acute UGIB.

Following promising initial results, a prospective RCT was performed. Seventy-one UGIB patients were randomly assigned to receive standard care including early endoscopic evaluation within 24 h or VCE using PillCam ESO 2 in the emergency room. The need for hospitalization was determined by the findings of VCE[34]. This study showed a greater than 70% reduction rate without serious adverse events in the VCE group. Comparing the VCE results with the initial GBS, hospital admissions were significantly reduced for patients recruited to receive the VCE. Based on these results, the authors considered VCE in the emergency room to be an appropriate screening tool to distinguish patients who do not need hospitalization.

Although the initial data seem to be promising, it would be premature to use VCE as a screening tool for decisions to hospitalize. To date, there is only one small RCT that supports using VCE as a tool for patient classification. In addition to an inappropriate duodenal visualization, the possibility of missing lesions in the fundus and other less accessible areas is a limitation of VCE. Moreover, it is difficult to train emergency doctors or specialists in for interpretation and set up of VCE in the emergency room[17].

**RISK STRATIFICATION AND PRE-ENDOSCOPIC ASSESSMENT FOR GASTROINTESTINAL BLEEDING**

In patients with suspected upper gastrointestinal bleeding including hematemesis or melena, treatment may be different according to the etiology of the bleeding. However, the evaluation of vital signs, hemodynamic status and appropriate fluid treatment are important in all patients[35]. If there are hypovolemic shock, rapid pulse rate, high blood urea nitrogen level, decreased urine volume at the time of presentation or previous history of acute bleeding, more aggressive initial monitoring, fluid treatment, and blood transfusion treatment are needed. However, if there is suspicion of massive bleeding, careful observation and follow up are necessary because early level of hemoglobin in acute bleeding may be normal[36].

The scoring system used when referring to the emergency department due to upper gastrointestinal bleeding can be divided into two types, one that includes endoscopic findings and the other that does not. The most commonly used scoring system is the Rockall score (RS) published by Rockall *et al*[37]In 1996. This scoring system predicts the likelihood of death within 30 d by using the five factors: patient age, accompanying shock, co-morbidities such as heart, liver, and kidney, causative diseases of bleeding, and endoscopic bleeding stigmata. However, since there is a disadvantage that the endoscopic findings must be known, in practice, the preendoscopic RS that can be calculated with the three findings except the etiology of the bleeding and endoscopic findings is used. This is useful for predicting rebleeding and mortality risk[38].

In addition, the Glasgow-Blatchford score (GBS) developed in 1882, which was calculated from patient's symptoms, blood test, physical examination, and accompanying diseases before endoscopy, is widely used to predict the need for transfusion, endoscopic treatment, rebleeding rate and prognosis[39]. In particular, this scoring system has the advantage of being able to quickly and simply measure in the emergency room due to blood urea, hemoglobin, systolic blood pressure, pulse rate, presence of melena or syncope, liver disease, and heart failure.

Recently, AIMS65, a simpler scoring system, has also been proposed, including albumin, prothrombin time, mental state, systolic blood pressure. It is easy to memorize, and it can be calculated objectively and easily[40]. In one study, mortality from AIMS65 scores ranged from 0.3% to 32%[41].

The initial treatment of patients with GI bleeding is to restore the stability of the hemodynamic circulation. In order to maintain blood vessel volume and hemodynamic stability, it is important to secure a large vein, and it is important to check whether it is accompanied by heart, kidney, and liver disease[35].

Although the nasogastric tube insertion is controversial, it can detect the need for immediate endoscopic hemostasis if blood is seen from the upper gastrointestinal hemorrhage to the nasogastric tube. However, it should be remembered that there may be a false negative due to duodenal hemorrhage[35]. One dose of antibiotic erythromycin administered 30-120 min before endoscopy is not recommended on a routine basis, but it is recommended to improve endoscopic visualization, reduce the need for transfusion and endoscopy, and reduce the length of hospital stay[42,43]

**THERAPEUTIC ROLE OF ENDOSCOPY**

In recent years, endoscopic techniques have improved the management of GIB, including peptic ulcer, variceal, diverticular, and angiodysplastic bleeding. Moreover, an increase in accessible and technologically advanced, well-trained, endoscopy center-related specialists has led to early diagnosis through endoscopic intervention[44].

Methods of endoscopic hemostasis for acute UGIB and LGIB include injection (usually diluted epinephrine or a special sclerosing agent), contact and non-contact thermal devices (unipolar or bipolar electrocoagulation, heater probes, and argon plasma coagulation), and mechanical devices (endoscopic clips and band ligation)[45]. Diluted epinephrine injections of 1:10000 to 1:20000 dilution facilitate primary hemostasis of active bleeding; to reduce the risk of rebleeding, mechanical or thermal therapy to obtain definite hemostasis should follow immediately as a secondary method[4,46]. Randomized trials are insufficient in assessing the endoscopic hemostatic effects on acute GIB. The choice of a hemostasis method is generally determined by the cause and location of GIB, the ability to access the site, and the experience of the endoscopist.

In the following, we will discuss the most clinically relevant methods of endoscopic treatment for the four major types of GIB and describe the most effective procedure.

***Peptic ulcer bleeding***

Peptic ulcer bleeding, which accounts for 30%-60% of UGIB, has been the most studied. Although the classifications for peptic ulcer bleeding were created a very long time ago, an endoscopic classification called Forrest classification is widely used as a standard for endoscopic treatment. In most cases in the Forrest classification, Ia to IIa lesions have a rebleeding rate greater than 50%, in most of which active endoscopic treatment should be performed[47,48].

However, the Forrest classification is over 40 years old; recently, de Groot *et al*[49] evaluated whether this classification is useful in predicting the rebleeding and mortality of peptic ulcer bleeding and conducted a study to assess whether it could be simplified. They have simplified the Forrest classification as high risk (Forrest Ia), increased risk (Forrest Ib-IIc), and low risk (Forrest III). The rate of rebleeding in a total of 397 patients was highest (59%) in Forrest Ia peptic ulcers, but the rebleeding rates in Ib and IIc were similar. In subgroup analysis, prediction of rebleeding using the Forrest classification is more reliable for gastric ulcers than for duodenal ulcers. Simplifying this classification can reduce interobserver variability in classifying lesions but requires confirmation studies[49].

Traditionally, three endoscopic treatment methods of peptic ulcer bleeding have been used: injection therapy, thermal therapy, and mechanical therapy. The question of whether monotherapy or combined modality therapy is more effective has been the subject of several trials and meta-analyses. The Cochrane review in 2014 evaluated 19 RCTs with 2033 patients and concluded that the second bleeding control method significantly reduced the risk of rebleeding and emergency surgery compared to epinephrine injection therapy alone[50]. Mortality was also reduced but was not statistically significant. Similar results were shown in other meta-analyses[51,52]. In a study published in 2016[52], involving 2,888 patients, hemoclips alone or injection therapy combined with thermal therapy were more effective than injection therapy alone. Thus, it was concluded that epinephrine injection therapy should not be used as a monotherapy but in conjunction with a secondary therapy. After endoscopic treatment, adverse outcomes including perforation and therapy-induced bleeding can occur. They may be more common in endoscopic therapy than in medical therapy alone, but a meta-analysis showed no statistically significant difference (0.8% *vs* 0.1%)[53].

After endoscopic treatment for spurting bleeding or exposed vessel lesion, which is known to be highly rebleeding, high dose PPI is known to be an important medication to prevent rebleeding[54]. However, according to recent study, risk of rebleeding associated with Forrest Ib is very less compared Forrest IIa and IIb and may not require high dose IV PPI after successful endotherapy[55].

***Variceal bleeding***

Variceal bleeding is a common and very serious complication of portal hypertension. In previous studies, variceal bleeding in patients with liver cirrhosis has been reported to result in a mortality rate of up to 50%[56]. The use of vasoactive drugs, endoscopic management, and prophylactic antibiotics has improved mortality, but esophageal varix bleeding is still associated with 20% mortality within 6 wk[9]. It is important to stabilize patients prior to endoscopic treatment for variceal bleeding and to maintain an intravenous line for hemodynamic stability and a hemoglobin level of at least 7-8 g/dL through blood volume resuscitation[57]. Administration of prophylactic antibiotics such as intravenous quinolone or ceftriaxone is also necessary and could lower systemic bacterial infection and reduce mortality[58]. Vasoactive drugs such as octreotide, somatostatin, and terlipressin are recommended to be administered as soon as possible[56].

Endoscopic variceal ligation (EVL) is the treatment of choice for esophageal variceal bleeding and secondary prevention. The diagnosis of variceal bleeding in the setting of active bleeding is based on the appearance of bleeding varices, stigmata of recent bleeding including an adherent clot over varix or platelet plug called by white nipple marks, or presence of varices without definite active bleeding focus[59]. In a recent meta-analysis of 1236 cases in 14 studies reported by Dai *et al*[60], EVL is better in terms of major outcome including rebleeding, variceal eradication, and complication rate compared with endoscopic injection sclerotherapy but not in mortality. Therefore, EVL is the most effective first choice for esophageal varix bleeding. After acute esophageal variceal bleeding, repeated endoscopy with EVL until varix eradication is recommended, usually requiring 2 to 4 sessions of therapy[61]. The optimal interval of each EVL for secondary prevention has been undefined and usually ranges from 2 to 8 wk in studies evaluating repeated EVLs for secondary prevention.

Post-EVL band-induced ulcer bleeding may occur as a complication of EVL. Sinclair *et al*[62] reported that the incidence was just 2.8%, but was significantly associated with mortality. A high MELD score (MELD is an abbreviation for Model for End-stage Liver Disease, which is calculated using serum bilirubin, prothrombin time, and serum creatinine) was associated with more frequent development of band-induced ulcer bleeding[62]. Transjugular intrahepatic portosystemic shunt (TIPS) or sclerotherapy can be considered as a treatment for band-induced ulcer bleeding, and pantoprazole for 10 d can reduce the ulcer size[63]. Moreover, rebleeding from band ulcers can be treated by hemostatic power or spray that used in management of peptic ulcer bleeding[64,65]. Recently, a study by Ibrahim *et al*[66] showed that immediate application of hemostatic powder is effective for early clinical course and endoscopic hemostasis in patients with acute initial variceal bleeding.

In addition, we could consider another management including esophageal balloon tamponade in patients of recurrent or refractory variceal hemorrhage despite of the most effective EVL treatment. The esophageal stent, which was mainly used for luminal GI stenosis, has been used in place of balloon in refractory variceal bleeding, showing statistically significant rate of treatment success and bleeding control[67]. As mentioned previously, TIPS treatment is used for recurrent and refractory variceal bleeding in patient with high-risk criteria (Child-Pugh B plus active bleeding at endoscopy or Child-Pugh C). However, early TIPS in a Child-Pugh B patient for recurrent variceal bleeding could be accelerating the development of acute-on-chronic liver failure and/or death. The careful decision of patients for TIPS is essential and other parameters should be considered, such as systemic inflammation, non-selective beta blocker-non-response and portal vein thrombosis[68].

***Diverticular bleeding***

The prevalence of colonic diverticula increases with aging, up to 30% at 50 years and 70% by 80 years[69,70]. Clinically significant bleeding occurs in 3%-15% of patients with colon diverticulosis, usually as a result of traumatic injury to the vasa recta at the neck or dome of the diverticulum. Nonsteroidal anti-inflammatory drugs (NSAIDs), aspirin, hypertension, and anticoagulants are known to be associated with diverticular bleeding[71]. Diverticular bleeding, which accounts for 20%-65% of LGIB, is known to stop spontaneously in about 75% of patients[72], and 25%-40% experience rebleeding within four years. Therefore, endoscopic treatment is required in patients with stigmata[73]. Only conservative therapy can be used in patients with a very high rate of rebleeding, and active endoscopic treatment is recommended and effective for long-term follow-up[24].

Various methods of endoscopic treatment have been used to treat colonic diverticular bleeding, including bipolar coagulation, epinephrine injection, clipping including the over-the-scope clip, and ligation such as endoscopic band ligation and endoscopic detachable snare ligation[4,22,74]. Due to lack of muscle layer in the colonic diverticulum, bipolar electrocoagulation is not recommended because of the risk of perforation. Epinephrine injection monotherapy has a high risk of rebleeding (20%)[74]. A very useful technique is to directly attach the clip to the neck of the diverticulum containing the bleeding stigmata[75]. Band ligation is a familiar method for endoscopists. Recently, many studies have reported band ligation as a safe and effective hemostatic method for diverticular bleeding[76]. Ishii *et al*[76] have reported that simple band ligation of diverticular bleeding can be performed by both endoscopic expert and trainee with similar safety, efficacy, and procedure time.

In a meta-analysis recently conducted by Ishii *et al*[74] to confirm the efficacy of endoscopic treatment for colonic diverticular bleeding, 16 studies of 384 colonic diverticular bleeding patients were analyzed. Ligation therapy was found to be more effective than clipping in terms of avoiding trans-arterial embolization. Surgery, coagulation, clipping, and ligation were equivocal in terms of effectiveness for initial hemostasis and early recurrent bleeding. However, most studies in meta-analysis have been retrospective in design and small in sample size, making them susceptible to recall and selection biases. A recent prospective study of recurrent diverticular bleeding showed that 1-year rebleeding was higher in clipping (37%) than in ligation (11.5%), suggesting that band ligation is superior to clipping for treatment and elimination of colonic diverticular bleeding[77]. However, ligation may be limited due to inadequate suction in the presence of a small orifice or a large dome, and these cases have reported a high prevalence of rebleeding. Therefore, further studies are required for its application in real clinical practice.

***Angiodysplastic bleeding***

The prevalence of colonic angiodysplasias have various clinical presentations; for example, 1%-2% in screening colonoscopy and 40%-50% in patients with hematochezia[78]. Studies have shown that angiodysplasias account for 3%-15% of LGIB. The incidence of angiodysplasias increases with age, and more than two-thirds of lesions are observed in patients > 70 years[46]. The cause of angiodysplasias is degenerative changes of submucosal vessels with chronic intermittent low-grade occlusion[79]. These vessels are mainly located in the right colon including the cecum and ascending colon. Colonoscopy can reveal multiple angiodysplasias, which appear as flat, red lesions ranging in size from 2 mm to a few centimeters with tree-like morphology from a central feeding vessel.

Risk factors for angiodysplasia bleeding include older age, combined morbidities, presence of multiple angiodysplastic lesions, and use of anticoagulants or antiplatelet agents[80,81]. Clinical presentation may occasionally have intermittent hematochezia, melena, or occult bleeding with anemia. The detection rate of angiodysplasias by colonoscopy is 80% based on sensitivity[82]. However, with the use of sedatives, mucosal blood flow could be reduced, and colonoscopy can make it difficult to detect these lesions[83].

Contact and non-contact thermal coagulation with argon plasma are useful for endoscopic treatment of angiodysplasias. Argon plasma coagulation can be a preferred technique due to its ease of application, the therapeutic potential of a large surface area, and predictable penetration depth of the colon wall[84]. A low power setting of 30 to 45 W and an argon flow rate of 1 L/min are used to reduce the risk of perforation to the thin wall of the right colon. The probe should preferably be 1 to 3 mm from the mucosal surface and should be applied at 1-2 s[25]. In follow-up data of 100 patients with angiodysplastic bleeding (including 31% colon lesions) for a median of 16 mo, argon plasma coagulation led to significantly improved hemoglobin level and reduced blood transfusion requirement without adverse events[84].

***Recent developments for endotherapy in patients with acute GI bleeding***

Various endoscopic therapies have been attempted in cases of failure of hemostasis due to general endoscopic treatment. The OTSC (Over-the-scope clip, Ovesco AG, Tübingen, Germany) system, which is inserted at the upper end of the endoscope, has been widely used in fistulas and perforations. However, it can be used in cases of continuous hemorrhage due to local injection or clipping[85]. In addition, the hemostasis of the bleeding site through the nano powder (Hemospray, Cook Medical, Winston-Salem, NC, USA) or starch (EndoClot Plus Inc., Santa Clara, CA, USA ) can be used when other hemostasis is not treated. Previously, it was difficult to distribute the powder or starch materials to the hemorrhagic lesion, but in recent years, disposable powder roots have been developed and can be used more easily[86,87].

**ENDOSCOPY FOR CRITICALLY ILL PATIENTS WITH SUSPECTED GIB**

***Bedside endoscopy for intensive care unit patients***

Patients in the intensive care unit (ICU) often have GIB from a variety of reasons. GIB in the ICU is an important event with serious complications that increase morbidity and mortality. Management of GIB in the ICU is difficult because most patients have complex poor prognostic factors; in most cases, they cannot be transferred to the endoscopy center. Therefore, bedside endoscopy is a good option for these patients[88,89].

In a recent study by Kim *et al*[88], 253 cases of bedside endoscopy and 69 cases of bedside colonoscopy were analyzed. The most common causes of UGIB were peptic ulcer and acute gastric mucosal lesion, and the causes of LGIB were ischemic colitis and rectal ulcer. The detection and treatment rate of bleeding focus were significantly increased in patients who underwent early upper endoscopy within 24 h. However, in patients with LGIB, early colonoscopy led to lower detection and hemostatic rate because of poor bowel preparation and bloody stool materials. Therefore, early upper endoscopy could be effective when UGIB is suspected in ICU patients, while in cases of colonoscopy, appropriate bowel preparation may first be necessary.

***Prophylactic endotracheal intubation before upper GI endoscopy***

Patients with UGIB have a particularly high risk of cardiopulmonary complications due to aspiration of blood and gastric contents and the presence of underlying comorbidities[90,91]. In a study in 2003 by Rudolph *et al*[92], high-risk patients with UGIB requiring ICU admission had 33.6% overall cardiopulmonary morbidity during hospitalization and 13.6% mortality. Upper GI endoscopy-related cardiopulmonary complications were common (4.1%), and new development of pulmonary infiltration was found in 14.1% of patients[92].

Prophylactic endotracheal intubation is performed to protect the airway and prevent aspiration during upper GI endoscopy and severe UGIB. It is thought to be effective in prevention of aspiration pneumonia, but there have been few studies. In a retrospective study conducted in 2009, of 307 patients with UGIB who received upper endoscopy, 53 underwent prophylactic endotracheal intubation, but cumulative incidence of cardiopulmonary complications, ICU or hospital length of stay and mortality were similar to non-intubated patients[93]. However, in a study by Hayat *et al*[94] in 2017, 200 patients were divided into groups of 100 based on need for intubation or not. In the intubation group, unplanned cardiopulmonary events were significantly higher than in the non-intubation group, and this difference between groups did not change after adjustment for presence of esophageal varices. Therefore, prophylactic endotracheal intubation should be carefully considered before upper GI endoscopy,

**THE ROLE OF ENDOSCOPY IN PROGNOSIS AFTER GIB**

***Is there a difference in prognosis between endoscopic and clinical findings?***

Endoscopic findings of GIB are observed, and successful hemostasis can improve the prognosis and increase the survival rate. However, endoscopic hemostasis is not always successful. If we know the factors that are likely to fail in endoscopic hemostasis, decisions can be made to change the modality.

In a previous report[95], the success of endoscopic treatment of peptic ulcer bleeding was reported to be 94%, followed by that of permanent hemostasis without rebleeding (82.5%). There was failure of endoscopic treatment or rebleeding in 17.5% of endoscopic treatments. The patients had significantly higher rates of active bleeding at the time of diagnosis, shock at admission, or low hemoglobin level. However, medication history, old age, and location of gastric ulcer had no effect on the failure rate of endoscopic bleeding control. In another large study involving injection and thermal therapy of 3386 patients with peptic ulcer bleeding, 98.6% had successful initial hemostasis, but 8.2% had rebleeding. Therefore, the final failure rate of bleeding control was 9.6%. When blood pressure was low, hemoglobin was less than 10 g/dL, fresh blood was observed in the stomach, and large or active ulcers were seen, the failure rate of endoscopic bleeding control was significantly higher[96]. In a study by Thomopoulos *et al*[97], 427 patients were endoscopically treated, with a failure rate of 20.1%. Endoscopic findings of spurting bleeding and duodenal ulcer on the posterior side or anastomosis site showed significant treatment failure. In summary, signs of severe bleeding, including shock, decreased hemoglobin level, fresh blood at the time of initial presentation, or ulcer with a large surface area and spurting blood, could lead to failure of the endoscopic procedure.

Variceal bleeding is affected by portal hypertension. The hepatic venous pressure gradient, which reflects portal pressure, is most important. In addition, the severity of liver disease reflected by the Child-Pugh class or MELD, encephalopathy, platelet count, history of alcoholism, and presence of portal vein thrombosis were found to be independent factors for failure of endoscopic variceal bleeding control[98,99]. Therefore, in high-risk patients with a high probability of failure of bleeding control, a preemptive TIPS should be prepared, and tamponade ballooning should be performed temporarily after retrials of endoscopic hemostasis[100]. Unlike bleeding in other diseases, variceal bleeding should be considered to be more affected by the severity of liver cirrhosis than by endoscopic findings[101].

The determinant of LGIB recurrence is the pattern used to achieve primary hemostasis. Predisposing factors of recurrent LGIB are primary hemostatic modality[102]; use of antiplatelet, anticoagulant agent, and NSAIDs; presence of chronic kidney disease or liver cirrhosis; and etiology of initial bleeding[4]. It is not clear how the proportional influence of these individual characteristics will affect the incidence of recurrent bleeding. In a retrospective study with 171 severe LGIB cases[103], the three causes of bleeding were diverticular bleeding, which was the most common cause, anorectal diseases, and angiodysplasia. In particular, 15% of the subjects were treated previously with antiplatelet agents and 9% with anticoagulants. During the mean follow-up period of 11 years, about one-third of the participants had recurrent LGIB. As noted in previous studies, LGIB is more likely to rebleed and affects older patients taking several medications. One of the most important points in diverticular bleeding and angiodysplasias bleeding, which comprise a large part of LGIB, is that they can stop spontaneously and rebleed at the same site or in other lesions.

***Is routine second-look endoscopy necessary?***

Recurrent bleeding occurs in 8%-15% of patients with peptic ulcer bleeding and increases mortality by 2 to 5 times. The goal of routine second-look endoscopy performed within 24 h after initial endoscopic hemostasis is to treat stigmata of peptic ulcer bleeding preemptively before rebleeding symptoms develop[17].

A meta-analysis based on eight prospective RCTs was conducted to evaluate whether rebleeding can be reduced by second-look endoscopy in very high-risk patients without high dose PPI[104]. The pooled data showed that second-look endoscopy reduced the need for surgery but not mortality. Moreover, there was no benefit in second-look endoscopy by subgroup analysis after exclusion of two trials with bleeding in high-risk patients[104,105]. In a recent randomized trial comparing second-look endoscopy and intravenous PPI infusion after endoscopic hemostasis for peptic ulcer bleeding[105], there were no differences in recurrence bleeding, need for surgery, and mortality between the two treatment strategies. In addition, second-look endoscopy did not appear to be cost-effective when offered to all patients.

The remaining problem is whether we can identify high-risk patients and obtain the benefit from second-look endoscopy with repeated endoscopic treatment for stigmata by the next day. In a study of 699 patients in Korea, use of NSAIDs, a large volume of transfused blood, and failure of second-look endoscopy were risk factors for rebleeding after endoscopic intervention[106]. A study in Taiwan, involving 316 patients who received high dose PPI after endoscopy, attempted to formulate predictive scores using endoscopic monotherapy and serum albumin level[107]. This score indicated that the receiver operating characteristic curve would help predict the need for routine second-look endoscopy, but the results were insufficient. However, a recent multicenter prospective study showed that the success of initial hemostasis, the use of NSAIDs, and the large number of blood transfusions were independent risk factors for rebleeding. Therefore, scheduled second-look endoscopy could be helpful for patient with unsatisfactory initial endoscopic hemostasis, use of NSAIDs, large amounts of blood transfusions[108].

Therefore, the risk assessment method and preemptive endoscopic treatment for selecting high-risk patients who require second-look endoscopy are not clear. However, since many clinicians are practicing prophylactic second-look endoscopy for patients with a high risk of rebleeding, further studies on risk classification and selecting the method for routine second-look endoscopy are needed.

**CONCLUSION**

The symptoms of bleeding in the GI tract that are encountered in real clinical practice are mainly melena, hematemesis, and hematochezia. When a patient with these symptoms presents to the emergency room, endoscopic diagnosis and treatment are considered together with appropriate initial resuscitation. For better prognosis in cases of suspected variceal bleeding, it is paramount that endoscopy is performed immediately after the patient is stabilized, and it would be sufficiently effective for endoscopy to be undertaken within 24 h from symptom development for non-variceal UGIB. In cases of suspected LGIB, sigmoidoscopy may be initially performed if there is a strong suspicion of anorectal bleeding. However, on the whole, full colonoscopy after bowel preparation is effective for distinguishing the cause and location of bleeding and treating with hemostasis.

There are three methods used to perform hemostasis by endoscopy: injection, thermal, and mechanical therapy. Using a mechanical method or injection therapy combined with other modalities, rather than injection therapy alone, increases the success rate of bleeding control. In patients in the ICU, bedside endoscopy may be effective, but prophylactic intubation is still controversial. Proper endoscopic hemostasis can affect prognosis and prevent rebleeding. Routine second-look endoscopy does not affect the outcome of hemostasis, but it may be helpful in selected patients with a high risk of rebleeding. From the emergency room to discharge of the patient, the contents of this review are summarized in Figure 1.

In conclusion, the role of endoscopy in GIB is very important, and many guidelines have been developed about endoscopic treatment for specific bleeding diseases. However, there are still parts that have not been established. Especially, further studies on prophylactic intubated endoscopy, routine second-look endoscopy and emergency capsule endoscopy issues are needed.

**REFERENCES**

1 **Abougergi MS**, Travis AC, Saltzman JR. The in-hospital mortality rate for upper GI hemorrhage has decreased over 2 decades in the United States: a nationwide analysis. *Gastrointest Endosc* 2015; **81**: 882-8.e1 [PMID: 25484324 DOI: 10.1016/j.gie.2014.09.027]

2 **Strate LL**, Ayanian JZ, Kotler G, Syngal S. Risk factors for mortality in lower intestinal bleeding. *Clin Gastroenterol Hepatol* 2008; **6**: 1004-10; quiz 955- [PMID: 18558513 DOI: 10.1016/j.cgh.2008.03.021]

3 **Fallah MA**, Prakash C, Edmundowicz S. Acute gastrointestinal bleeding. *Med Clin North Am* 2000; **84**: 1183-1208 [PMID: 11026924 DOI: 10.1016/S0025-7125(05)70282-0]

4 **Strate LL**, Gralnek IM. ACG Clinical Guideline: Management of Patients With Acute Lower Gastrointestinal Bleeding. *Am J Gastroenterol* 2016; **111**: 459-474 [PMID: 26925883 DOI: 10.1038/ajg.2016.41]

5 **Wilcox CM**, Alexander LN, Cotsonis G. A prospective characterization of upper gastrointestinal hemorrhage presenting with hematochezia. *Am J Gastroenterol* 1997; **92**: 231-235 [PMID: 9040197]

6 **Kumar NL**, Travis AC, Saltzman JR. Initial management and timing of endoscopy in nonvariceal upper GI bleeding. *Gastrointest Endosc* 2016; **84**: 10-17 [PMID: 26944336 DOI: 10.1016/j.gie.2016.02.031]

7 **Kapoor A**, Dharel N, Sanyal AJ. Endoscopic Diagnosis and Therapy in Gastroesophageal Variceal Bleeding. *Gastrointest Endosc Clin N Am* 2015; **25**: 491-507 [PMID: 26142034 DOI: 10.1016/j.giec.2015.03.004]

8 **Garcia-Tsao G**, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. *Hepatology* 2017; **65**: 310-335 [PMID: 27786365 DOI: 10.1002/hep.28906]

9 **de Franchis R**, Primignani M. Natural history of portal hypertension in patients with cirrhosis. *Clin Liver Dis* 2001; **5**: 645-663 [PMID: 11565135 DOI: 10.1016/S1089-3261(05)70186-0]

10 **Sung JJ**, Chan FK, Chen M, Ching JY, Ho KY, Kachintorn U, Kim N, Lau JY, Menon J, Rani AA, Reddy N, Sollano J, Sugano K, Tsoi KK, Wu CY, Yeomans N, Vakil N, Goh KL; Asia-Pacific Working Group. Asia-Pacific Working Group consensus on non-variceal upper gastrointestinal bleeding. *Gut* 2011; **60**: 1170-1177 [PMID: 21471571 DOI: 10.1136/gut.2010.230292]

11 **Karstensen JG**, Ebigbo A, Aabakken L, Dinis-Ribeiro M, Gralnek I, Le Moine O, Vilmann P, Ijoma U, Anigbo G, Afihene M, Duduyemi B, Ponchon T, Hassan C. Nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Cascade Guideline. *Endosc Int Open* 2018; **6**: E1256-E1263 [PMID: 30302383 DOI: 10.1055/a-0677-2084]

12 **Cipolletta L**, Cipolletta F, Granata A, Ligresti D, Barresi L, Tarantino I, Traina M. What Is the Best Endoscopic Strategy in Acute Non-variceal Gastrointestinal Bleeding? *Curr Treat Options Gastroenterol* 2018; **16**: 363-375 [PMID: 30229463 DOI: 10.1007/s11938-018-0192-0]

13 **Kumar NL**, Cohen AJ, Nayor J, Claggett BL, Saltzman JR. Timing of upper endoscopy influences outcomes in patients with acute nonvariceal upper GI bleeding. *Gastrointest Endosc* 2017; **85**: 945-952.e1 [PMID: 27693643 DOI: 10.1016/j.gie.2016.09.029]

14 **Laursen SB**, Leontiadis GI, Stanley AJ, Møller MH, Hansen JM, Schaffalitzky de Muckadell OB. Relationship between timing of endoscopy and mortality in patients with peptic ulcer bleeding: a nationwide cohort study. *Gastrointest Endosc* 2017; **85**: 936-944.e3 [PMID: 27623102 DOI: 10.1016/j.gie.2016.08.049]

15 **Jairath V**, Kahan BC, Logan RF, Hearnshaw SA, Doré CJ, Travis SP, Murphy MF, Palmer KR. Outcomes following acute nonvariceal upper gastrointestinal bleeding in relation to time to endoscopy: results from a nationwide study. *Endoscopy* 2012; **44**: 723-730 [PMID: 22752889 DOI: 10.1055/s-0032-1309736]

16 **Lim LG**, Ho KY, Chan YH, Teoh PL, Khor CJ, Lim LL, Rajnakova A, Ong TZ, Yeoh KG. Urgent endoscopy is associated with lower mortality in high-risk but not low-risk nonvariceal upper gastrointestinal bleeding. *Endoscopy* 2011; **43**: 300-306 [PMID: 21360421 DOI: 10.1055/s-0030-1256110]

17 **Sung JJ**, Chiu PW, Chan FKL, Lau JY, Goh KL, Ho LH, Jung HY, Sollano JD, Gotoda T, Reddy N, Singh R, Sugano K, Wu KC, Wu CY, Bjorkman DJ, Jensen DM, Kuipers EJ, Lanas A. Asia-Pacific working group consensus on non-variceal upper gastrointestinal bleeding: an update 2018. *Gut* 2018; **67**: 1757-1768 [PMID: 29691276 DOI: 10.1136/gutjnl-2018-316276]

18 **Korkis AM**, McDougall CJ. Rectal bleeding in patients less than 50 years of age. *Dig Dis Sci* 1995; **40**: 1520-1523 [PMID: 7628276 DOI: 10.1007/BF02285201]

19 **Angtuaco TL**, Reddy SK, Drapkin S, Harrell LE, Howden CW. The utility of urgent colonoscopy in the evaluation of acute lower gastrointestinal tract bleeding: a 2-year experience from a single center. *Am J Gastroenterol* 2001; **96**: 1782-1785 [PMID: 11419829 DOI: 10.1111/j.1572-0241.2001.03871.x]

20 **Lhewa DY**, Strate LL. Pros and cons of colonoscopy in management of acute lower gastrointestinal bleeding. *World J Gastroenterol* 2012; **18**: 1185-1190 [PMID: 22468081 DOI: 10.3748/wjg.v18.i11.1185]

21 **Seth A**, Khan MA, Nollan R, Gupta D, Kamal S, Singh U, Kamal F, Howden CW. Does Urgent Colonoscopy Improve Outcomes in the Management of Lower Gastrointestinal Bleeding? *Am J Med Sci* 2017; **353**: 298-306 [PMID: 28262219 DOI: 10.1016/j.amjms.2016.11.007]

22 **Kouanda AM**, Somsouk M, Sewell JL, Day LW. Urgent colonoscopy in patients with lower GI bleeding: a systematic review and meta-analysis. *Gastrointest Endosc* 2017; **86**: 107-117.e1 [PMID: 28174123 DOI: 10.1016/j.gie.2017.01.035]

23 **Sengupta N**, Tapper EB, Feuerstein JD. Early Versus Delayed Colonoscopy in Hospitalized Patients With Lower Gastrointestinal Bleeding: A Meta-Analysis. *J Clin Gastroenterol* 2017; **51**: 352-359 [PMID: 27466163 DOI: 10.1097/MCG.0000000000000602]

24 **Jensen DM**, Machicado GA, Jutabha R, Kovacs TO. Urgent colonoscopy for the diagnosis and treatment of severe diverticular hemorrhage. *N Engl J Med* 2000; **342**: 78-82 [PMID: 10631275 DOI: 10.1056/nejm200001133420202]

25 **Wong Kee Song LM**, Baron TH. Endoscopic management of acute lower gastrointestinal bleeding. *Am J Gastroenterol* 2008; **103**: 1881-1887 [PMID: 18796089 DOI: 10.1111/j.1572-0241.2008.02075.x]

26 **Laine L**, Shah A. Randomized trial of urgent vs. elective colonoscopy in patients hospitalized with lower GI bleeding. *Am J Gastroenterol* 2010; **105**: 2636-41; quiz 2642 [PMID: 20648004 DOI: 10.1038/ajg.2010.277]

27 **Green BT**, Rockey DC, Portwood G, Tarnasky PR, Guarisco S, Branch MS, Leung J, Jowell P. Urgent colonoscopy for evaluation and management of acute lower gastrointestinal hemorrhage: a randomized controlled trial. *Am J Gastroenterol* 2005; **100**: 2395-2402 [PMID: 16279891 DOI: 10.1111/j.1572-0241.2005.00306.x]

28 **Repaka A**, Atkinson MR, Faulx AL, Isenberg GA, Cooper GS, Chak A, Wong RC. Immediate unprepared hydroflush colonoscopy for severe lower GI bleeding: a feasibility study. *Gastrointest Endosc* 2012; **76**: 367-373 [PMID: 22658390 DOI: 10.1016/j.gie.2012.03.1391]

29 **Niikura R**, Nagata N, Shimbo T, Sakurai T, Aoki T, Moriyasu S, Sekine K, Okubo H, Watanabe K, Yokoi C, Yamada A, Hirata Y, Koike K, Akiyama J, Uemura N. Adverse Events during Bowel Preparation and Colonoscopy in Patients with Acute Lower Gastrointestinal Bleeding Compared with Elective Non-Gastrointestinal Bleeding. *PLoS One* 2015; **10**: e0138000 [PMID: 26368562 DOI: 10.1371/journal.pone.0138000]

30 **Pennazio M**, Spada C, Eliakim R, Keuchel M, May A, Mulder CJ, Rondonotti E, Adler SN, Albert J, Baltes P, Barbaro F, Cellier C, Charton JP, Delvaux M, Despott EJ, Domagk D, Klein A, McAlindon M, Rosa B, Rowse G, Sanders DS, Saurin JC, Sidhu R, Dumonceau JM, Hassan C, Gralnek IM. Small-bowel capsule endoscopy and device-assisted enteroscopy for diagnosis and treatment of small-bowel disorders: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. *Endoscopy* 2015; **47**: 352-376 [PMID: 25826168 DOI: 10.1055/s-0034-1391855]

31 **Lin S**, Rockey DC. Obscure gastrointestinal bleeding. *Gastroenterol Clin North Am* 2005; **34**: 679-698 [PMID: 16303577 DOI: 10.1016/j.gtc.2005.08.005]

32 **Kim JH**, Moon W. Optimal Diagnostic Approaches for Patients with Suspected Small Bowel Disease. *Clin Endosc* 2016; **49**: 364-369 [PMID: 27334413 DOI: 10.5946/ce.2016.074]

33 **Gralnek IM**, Ching JY, Maza I, Wu JC, Rainer TH, Israelit S, Klein A, Chan FK, Ephrath H, Eliakim R, Peled R, Sung JJ. Capsule endoscopy in acute upper gastrointestinal hemorrhage: a prospective cohort study. *Endoscopy* 2013; **45**: 12-19 [PMID: 23254402 DOI: 10.1055/s-0032-1325933]

34 **Sung JJ**, Tang RS, Ching JY, Rainer TH, Lau JY. Use of capsule endoscopy in the emergency department as a triage of patients with GI bleeding. *Gastrointest Endosc* 2016; **84**: 907-913 [PMID: 27156655 DOI: 10.1016/j.gie.2016.04.043]

35 **Cai JX**, Saltzman JR. Initial Assessment, Risk Stratification, and Early Management of Acute Nonvariceal Upper Gastrointestinal Hemorrhage. *Gastrointest Endosc Clin N Am* 2018; **28**: 261-275 [PMID: 29933774 DOI: 10.1016/j.giec.2018.02.001]

36 **Kim JS,** Kim BW. Risk Strategy in Non-Variceal Upper Gastrointestinal Bleeding. *Korean J Helicobacter Up Gastrointest Res* 2016; **16**: 173-177 [DOI: 10.7704/kjhugr.2016.16.4.173]

37 **Rockall TA**, Logan RF, Devlin HB, Northfield TC. Risk assessment after acute upper gastrointestinal haemorrhage. *Gut* 1996; **38**: 316-321 [PMID: 8675081 DOI: 10.1136/gut.38.3.316]

38 **Wang CY**, Qin J, Wang J, Sun CY, Cao T, Zhu DD. Rockall score in predicting outcomes of elderly patients with acute upper gastrointestinal bleeding. *World J Gastroenterol* 2013; **19**: 3466-3472 [PMID: 23801840 DOI: 10.3748/wjg.v19.i22.3466]

39 **Blatchford O**, Davidson LA, Murray WR, Blatchford M, Pell J. Acute upper gastrointestinal haemorrhage in west of Scotland: case ascertainment study. *BMJ* 1997; **315**: 510-514 [PMID: 9329304 DOI: 10.1136/bmj.315.7107.510]

40 **Yaka E**, Yılmaz S, Doğan NÖ, Pekdemir M. Comparison of the Glasgow-Blatchford and AIMS65 scoring systems for risk stratification in upper gastrointestinal bleeding in the emergency department. *Acad Emerg Med* 2015; **22**: 22-30 [PMID: 25556538 DOI: 10.1111/acem.12554]

41 **Saltzman JR**, Tabak YP, Hyett BH, Sun X, Travis AC, Johannes RS. A simple risk score accurately predicts in-hospital mortality, length of stay, and cost in acute upper GI bleeding. *Gastrointest Endosc* 2011; **74**: 1215-1224 [PMID: 21907980 DOI: 10.1016/j.gie.2011.06.024]

42 **Na HK**, Jung HY, Seo DW, Lim H, Ahn JY, Lee JH, Kim DH, Choi KD, Song HJ, Lee GH, Kim JH. Erythromycin infusion prior to endoscopy for acute nonvariceal upper gastrointestinal bleeding: a pilot randomized controlled trial. *Korean J Intern Med* 2017; **32**: 1002-1009 [PMID: 28352063 DOI: 10.3904/kjim.2016.117]

43 **Carbonell N**, Pauwels A, Serfaty L, Boelle PY, Becquemont L, Poupon R. Erythromycin infusion prior to endoscopy for acute upper gastrointestinal bleeding: a randomized, controlled, double-blind trial. *Am J Gastroenterol* 2006; **101**: 1211-1215 [PMID: 16771939 DOI: 10.1111/j.1572-0241.2006.00582.x]

44 **Troland D**, Stanley A. Endotherapy of Peptic Ulcer Bleeding. *Gastrointest Endosc Clin N Am* 2018; **28**: 277-289 [PMID: 29933775 DOI: 10.1016/j.giec.2018.02.002]

45 **Asge Technology Committee.**, Conway JD, Adler DG, Diehl DL, Farraye FA, Kantsevoy SV, Kaul V, Kethu SR, Kwon RS, Mamula P, Rodriguez SA, Tierney WM. Endoscopic hemostatic devices. *Gastrointest Endosc* 2009; **69**: 987-996 [PMID: 19410037 DOI: 10.1016/j.gie.2008.12.251]

46 **ASGE Standards of Practice Committee**, Pasha SF, Shergill A, Acosta RD, Chandrasekhara V, Chathadi KV, Early D, Evans JA, Fisher D, Fonkalsrud L, Hwang JH, Khashab MA, Lightdale JR, Muthusamy VR, Saltzman JR, Cash BD. The role of endoscopy in the patient with lower GI bleeding. *Gastrointest Endosc* 2014; **79**: 875-885 [PMID: 24703084 DOI: 10.1016/j.gie.2013.10.039]

47 **Forrest JA**, Finlayson ND, Shearman DJ. Endoscopy in gastrointestinal bleeding. *Lancet* 1974; **2**: 394-397 [PMID: 4136718 DOI: 10.1016/S0140-6736(74)91770-X]

48 **Laine L**. Clinical Practice. Upper Gastrointestinal Bleeding Due to a Peptic Ulcer. *N Engl J Med* 2016; **374**: 2367-2376 [PMID: 27305194 DOI: 10.1056/NEJMcp1514257]

49 **de Groot NL**, van Oijen MG, Kessels K, Hemmink M, Weusten BL, Timmer R, Hazen WL, van Lelyveld N, Vermeijden RR, Curvers WL, Baak BC, Verburg R, Bosman JH, de Wijkerslooth LR, de Rooij J, Venneman NG, Pennings M, van Hee K, Scheffer BC, van Eijk RL, Meiland R, Siersema PD, Bredenoord AJ. Reassessment of the predictive value of the Forrest classification for peptic ulcer rebleeding and mortality: can classification be simplified? *Endoscopy* 2014; **46**: 46-52 [PMID: 24218308 DOI: 10.1055/s-0033-1344884]

50 **Vergara M**, Bennett C, Calvet X, Gisbert JP. Epinephrine injection versus epinephrine injection and a second endoscopic method in high-risk bleeding ulcers. *Cochrane Database Syst Rev* 2014: CD005584 [PMID: 25308912 DOI: 10.1002/14651858.CD005584.pub3]

51 **Barkun AN**, Martel M, Toubouti Y, Rahme E, Bardou M. Endoscopic hemostasis in peptic ulcer bleeding for patients with high-risk lesions: a series of meta-analyses. *Gastrointest Endosc* 2009; **69**: 786-799 [PMID: 19152905 DOI: 10.1016/j.gie.2008.05.031]

52 **Baracat F**, Moura E, Bernardo W, Pu LZ, Mendonça E, Moura D, Baracat R, Ide E. Endoscopic hemostasis for peptic ulcer bleeding: systematic review and meta-analyses of randomized controlled trials. *Surg Endosc* 2016; **30**: 2155-2168 [PMID: 26487199 DOI: 10.1007/s00464-015-4542-x]

53 **Laine L**, McQuaid KR. Endoscopic therapy for bleeding ulcers: an evidence-based approach based on meta-analyses of randomized controlled trials. *Clin Gastroenterol Hepatol* 2009; **7**: 33-47; quiz 1-2 [PMID: 18986845 DOI: 10.1016/j.cgh.2008.08.016]

54 **Gralnek IM**, Dumonceau JM, Kuipers EJ, Lanas A, Sanders DS, Kurien M, Rotondano G, Hucl T, Dinis-Ribeiro M, Marmo R, Racz I, Arezzo A, Hoffmann RT, Lesur G, de Franchis R, Aabakken L, Veitch A, Radaelli F, Salgueiro P, Cardoso R, Maia L, Zullo A, Cipolletta L, Hassan C. Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. *Endoscopy* 2015; **47**: a1-46 [PMID: 26417980 DOI: 10.1055/s-0034-1393172]

55 **Jensen DM**, Eklund S, Persson T, Ahlbom H, Stuart R, Barkun AN, Kuipers EJ, Mössner J, Lau JY, Sung JJ, Kilhamn J, Lind T. Reassessment of Rebleeding Risk of Forrest IB (Oozing) Peptic Ulcer Bleeding in a Large International Randomized Trial. *Am J Gastroenterol* 2017; **112**: 441-446 [PMID: 28094314 DOI: 10.1038/ajg.2016.582]

56 **Hwang JH**, Shergill AK, Acosta RD, Chandrasekhara V, Chathadi KV, Decker GA, Early DS, Evans JA, Fanelli RD, Fisher DA, Foley KQ, Fonkalsrud L, Jue T, Khashab MA, Lightdale JR, Muthusamy VR, Pasha SF, Saltzman JR, Sharaf R, Cash BD; American Society for Gastrointestinal Endoscopy. The role of endoscopy in the management of variceal hemorrhage. *Gastrointest Endosc* 2014; **80**: 221-227 [PMID: 25034836 DOI: 10.1016/j.gie.2013.07.023]

57 **de Franchis R**; Baveno V Faculty. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. *J Hepatol* 2010; **53**: 762-768 [PMID: 20638742 DOI: 10.1016/j.jhep.2010.06.004]

58 **Soares-Weiser K**, Brezis M, Tur-Kaspa R, Leibovici L. Antibiotic prophylaxis for cirrhotic patients with gastrointestinal bleeding. *Cochrane Database Syst Rev* 2002: CD002907 [PMID: 12076458 DOI: 10.1002/14651858.Cd002907]

59 **Sarin SK**, Kumar A, Angus PW, Baijal SS, Baik SK, Bayraktar Y, Chawla YK, Choudhuri G, Chung JW, de Franchis R, de Silva HJ, Garg H, Garg PK, Helmy A, Hou MC, Jafri W, Jia JD, Lau GK, Li CZ, Lui HF, Maruyama H, Pandey CM, Puri AS, Rerknimitr R, Sahni P, Saraya A, Sharma BC, Sharma P, Shiha G, Sollano JD, Wu J, Xu RY, Yachha SK, Zhang C; Asian Pacific Association for the Study of the Liver (APASL) Working Party on Portal Hypertension. Diagnosis and management of acute variceal bleeding: Asian Pacific Association for Study of the Liver recommendations. *Hepatol Int* 2011; **5**: 607-624 [PMID: 21484145 DOI: 10.1007/s12072-010-9236-9]

60 **Dai C**, Liu WX, Jiang M, Sun MJ. Endoscopic variceal ligation compared with endoscopic injection sclerotherapy for treatment of esophageal variceal hemorrhage: a meta-analysis. *World J Gastroenterol* 2015; **21**: 2534-2541 [PMID: 25741164 DOI: 10.3748/wjg.v21.i8.2534]

61 **Garcia-Tsao G**, Sanyal AJ, Grace ND, Carey W; Practice Guidelines Committee of the American Association for the Study of Liver Diseases; Practice Parameters Committee of the American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. *Hepatology* 2007; **46**: 922-938 [PMID: 17879356 DOI: 10.1002/hep.21907]

62 **Sinclair M**, Vaughan R, Angus PW, Gow PJ, Parker F, Hey P, Efthymiou M. Risk factors for band-induced ulcer bleeding after prophylactic and therapeutic endoscopic variceal band ligation. *Eur J Gastroenterol Hepatol* 2015; **27**: 928-932 [PMID: 25951490 DOI: 10.1097/MEG.0000000000000387]

63 **Shaheen NJ**, Stuart E, Schmitz SM, Mitchell KL, Fried MW, Zacks S, Russo MW, Galanko J, Shrestha R. Pantoprazole reduces the size of postbanding ulcers after variceal band ligation: a randomized, controlled trial. *Hepatology* 2005; **41**: 588-594 [PMID: 15726658 DOI: 10.1002/hep.20593]

64 **Sanglodkar UA**, Jothimani D, Rela M. Hemospray for recurrent esophageal band ulcer bleeding. *Clin Exp Hepatol* 2018; **4**: 46-48 [PMID: 29594199 DOI: 10.5114/ceh.2018.73668]

65 **Ibrahim M**, El-Mikkawy A, Abdalla H, Mostafa I, Devière J. Management of acute variceal bleeding using hemostatic powder. *United European Gastroenterol J* 2015; **3**: 277-283 [PMID: 26137303 DOI: 10.1177/2050640615570148]

66 **Ibrahim M**, El-Mikkawy A, Abdel Hamid M, Abdalla H, Lemmers A, Mostafa I, Devière J. Early application of haemostatic powder added to standard management for oesophagogastric variceal bleeding: a randomised trial. *Gut* 2018 [PMID: 29730601 DOI: 10.1136/gutjnl-2017-314653]

67 **Escorsell À**, Pavel O, Cárdenas A, Morillas R, Llop E, Villanueva C, Garcia-Pagán JC, Bosch J; Variceal Bleeding Study Group. Esophageal balloon tamponade versus esophageal stent in controlling acute refractory variceal bleeding: A multicenter randomized, controlled trial. *Hepatology* 2016; **63**: 1957-1967 [PMID: 26600191 DOI: 10.1002/hep.28360]

68 **Trebicka J**. Emergency TIPS in a Child-Pugh B patient: When does the window of opportunity open and close? *J Hepatol* 2017; **66**: 442-450 [PMID: 27984174 DOI: 10.1016/j.jhep.2016.10.025]

69 **Feuerstein JD**, Falchuk KR. Diverticulosis and Diverticulitis. *Mayo Clin Proc* 2016; **91**: 1094-1104 [PMID: 27156370 DOI: 10.1016/j.mayocp.2016.03.012]

70 **Wensaas KA**, Hungin AP. Diverticular Disease in the Primary Care Setting. *J Clin Gastroenterol* 2016; **50 Suppl 1**: S86-S88 [PMID: 27622376 DOI: 10.1097/MCG.0000000000000596]

71 **Lee KK**, Shah SM, Moser MA. Risk factors predictive of severe diverticular hemorrhage. *Int J Surg* 2011; **9**: 83-85 [PMID: 20937418 DOI: 10.1016/j.ijsu.2010.09.011]

72 **McGuire HH Jr**. Bleeding colonic diverticula. A reappraisal of natural history and management. *Ann Surg* 1994; **220**: 653-656 [PMID: 7979613 DOI: 10.1097/00000658-199411000-00008]

73 **Jensen DM**, Ohning GV, Kovacs TO, Jutabha R, Ghassemi K, Dulai GS, Machicado GA. Natural history of definitive diverticular hemorrhage based on stigmata of recent hemorrhage and colonoscopic Doppler blood flow monitoring for risk stratification and definitive hemostasis. *Gastrointest Endosc* 2016; **83**: 416-423 [PMID: 26227931 DOI: 10.1016/j.gie.2015.07.033]

74 **Ishii N**, Omata F, Nagata N, Kaise M. Effectiveness of endoscopic treatments for colonic diverticular bleeding. *Gastrointest Endosc* 2018; **87**: 58-66 [PMID: 28843587 DOI: 10.1016/j.gie.2017.08.013]

75 **Soetikno R**, Ishii N, Kolb JM, Hammad H, Kaltenbach T. The Role of Endoscopic Hemostasis Therapy in Acute Lower Gastrointestinal Hemorrhage. *Gastrointest Endosc Clin N Am* 2018; **28**: 391-408 [PMID: 29933783 DOI: 10.1016/j.giec.2018.02.010]

76 **Ishii N**, Setoyama T, Deshpande GA, Omata F, Matsuda M, Suzuki S, Uemura M, Iizuka Y, Fukuda K, Suzuki K, Fujita Y. Endoscopic band ligation for colonic diverticular hemorrhage. *Gastrointest Endosc* 2012; **75**: 382-387 [PMID: 21944311 DOI: 10.1016/j.gie.2011.07.030]

77 **Nagata N**, Ishii N, Kaise M, Shimbo T, Sakurai T, Akiyama J, Uemura N. Long-term recurrent bleeding risk after endoscopic therapy for definitive colonic diverticular bleeding: band ligation versus clipping. *Gastrointest Endosc* 2018; **88**: 841-853.e4 [PMID: 30036505 DOI: 10.1016/j.gie.2018.07.018]

78 **Foutch PG**, Rex DK, Lieberman DA. Prevalence and natural history of colonic angiodysplasia among healthy asymptomatic people. *Am J Gastroenterol* 1995; **90**: 564-567 [PMID: 7717311]

79 **Boley SJ**, Sammartano R, Adams A, DiBiase A, Kleinhaus S, Sprayregen S. On the nature and etiology of vascular ectasias of the colon. Degenerative lesions of aging. *Gastroenterology* 1977; **72**: 650-660 [PMID: 300063]

80 **Sekino Y**, Endo H, Yamada E, Sakai E, Ohkubo H, Higurashi T, Iida H, Hosono K, Takahashi H, Koide T, Nonaka T, Abe Y, Gotoh E, Maeda S, Nakajima A, Inamori M. Clinical associations and risk factors for bleeding from colonic angiectasia: a case-controlled study. *Colorectal Dis* 2012; **14**: e740-e746 [PMID: 22709354 DOI: 10.1111/j.1463-1318.2012.03132.x]

81 **Strate LL**, Liu YL, Huang ES, Giovannucci EL, Chan AT. Use of aspirin or nonsteroidal anti-inflammatory drugs increases risk for diverticulitis and diverticular bleeding. *Gastroenterology* 2011; **140**: 1427-1433 [PMID: 21320500 DOI: 10.1053/j.gastro.2011.02.004]

82 **Strate LL**. Lower GI bleeding: epidemiology and diagnosis. *Gastroenterol Clin North Am* 2005; **34**: 643-664 [PMID: 16303575 DOI: 10.1016/j.gtc.2005.08.007]

83 **Brandt LJ**, Spinnell MK. Ability of naloxone to enhance the colonoscopic appearance of normal colon vasculature and colon vascular ectasias. *Gastrointest Endosc* 1999; **49**: 79-83 [PMID: 9869727 DOI: 10.1016/S0016-5107(99)70449-9]

84 **Kwan V**, Bourke MJ, Williams SJ, Gillespie PE, Murray MA, Kaffes AJ, Henriquez MS, Chan RO. Argon plasma coagulation in the management of symptomatic gastrointestinal vascular lesions: experience in 100 consecutive patients with long-term follow-up. *Am J Gastroenterol* 2006; **101**: 58-63 [PMID: 16405534 DOI: 10.1111/j.1572-0241.2006.00370.x]

85 **Kirschniak A**, Kratt T, Stüker D, Braun A, Schurr MO, Königsrainer A. A new endoscopic over-the-scope clip system for treatment of lesions and bleeding in the GI tract: first clinical experiences. *Gastrointest Endosc* 2007; **66**: 162-167 [PMID: 17591492 DOI: 10.1016/j.gie.2007.01.034]

86 **Sinha R**, Lockman KA, Church NI, Plevris JN, Hayes PC. The use of hemostatic spray as an adjunct to conventional hemostatic measures in high-risk nonvariceal upper GI bleeding (with video). *Gastrointest Endosc* 2016; **84**: 900-906.e3 [PMID: 27108061 DOI: 10.1016/j.gie.2016.04.016]

87 **Beg S**, Al-Bakir I, Bhuva M, Patel J, Fullard M, Leahy A. Early clinical experience of the safety and efficacy of EndoClot in the management of non-variceal upper gastrointestinal bleeding. *Endosc Int Open* 2015; **3**: E605-E609 [PMID: 26716120 DOI: 10.1055/s-0034-1393087]

88 **Kim JH**, Kim JH, Chun J, Lee C, Im JP, Kim JS. Early versus late bedside endoscopy for gastrointestinal bleeding in critically ill patients. *Korean J Intern Med* 2018; **33**: 304-312 [PMID: 28286937 DOI: 10.3904/kjim.2016.182]

89 **Jean-Baptiste S**, Messika J, Hajage D, Gaudry S, Barbieri J, Duboc H, Dreyfuss D, Coffin B, Ricard JD. Clinical impact of upper gastrointestinal endoscopy in critically ill patients with suspected bleeding. *Ann Intensive Care* 2018; **8**: 75 [PMID: 29974284 DOI: 10.1186/s13613-018-0423-5]

90 **Arrowsmith JB**, Gerstman BB, Fleischer DE, Benjamin SB. Results from the American Society for Gastrointestinal Endoscopy/U.S. Food and Drug Administration collaborative study on complication rates and drug use during gastrointestinal endoscopy. *Gastrointest Endosc* 1991; **37**: 421-427 [PMID: 1833259 DOI: 10.1016/S0016-5107(91)70773-6]

91 **Sharma VK**, Nguyen CC, Crowell MD, Lieberman DA, de Garmo P, Fleischer DE. A national study of cardiopulmonary unplanned events after GI endoscopy. *Gastrointest Endosc* 2007; **66**: 27-34 [PMID: 17591470 DOI: 10.1016/j.gie.2006.12.040]

92 **Rudolph SJ**, Landsverk BK, Freeman ML. Endotracheal intubation for airway protection during endoscopy for severe upper GI hemorrhage. *Gastrointest Endosc* 2003; **57**: 58-61 [PMID: 12518132 DOI: 10.1067/mge.2003.46]

93 **Rehman A**, Iscimen R, Yilmaz M, Khan H, Belsher J, Gomez JF, Hanson AC, Afessa B, Baron TH Sr, Gajic O. Prophylactic endotracheal intubation in critically ill patients undergoing endoscopy for upper GI hemorrhage. *Gastrointest Endosc* 2009; **69**: e55-e59 [PMID: 19481643 DOI: 10.1016/j.gie.2009.03.002]

94 **Hayat U**, Lee PJ, Ullah H, Sarvepalli S, Lopez R, Vargo JJ. Association of prophylactic endotracheal intubation in critically ill patients with upper GI bleeding and cardiopulmonary unplanned events. *Gastrointest Endosc* 2017; **86**: 500-509.e1 [PMID: 28011279 DOI: 10.1016/j.gie.2016.12.008]

95 **Choudari CP**, Rajgopal C, Elton RA, Palmer KR. Failures of endoscopic therapy for bleeding peptic ulcer: an analysis of risk factors. *Am J Gastroenterol* 1994; **89**: 1968-1972 [PMID: 7942719]

96 **Wong SK**, Yu LM, Lau JY, Lam YH, Chan AC, Ng EK, Sung JJ, Chung SC. Prediction of therapeutic failure after adrenaline injection plus heater probe treatment in patients with bleeding peptic ulcer. *Gut* 2002; **50**: 322-325 [PMID: 11839708 DOI: 10.1136/gut.50.3.322]

97 **Thomopoulos KC**, Mitropoulos JA, Katsakoulis EC, Vagianos CE, Mimidis KP, Hatziargiriou MN, Nikolopoulou VN. Factors associated with failure of endoscopic injection haemostasis in bleeding peptic ulcers. *Scand J Gastroenterol* 2001; **36**: 664-668 [PMID: 11424328 DOI: 10.1080/003655201750163231]

98 **La Mura V**, Nicolini A, Tosetti G, Primignani M. Cirrhosis and portal hypertension: The importance of risk stratification, the role of hepatic venous pressure gradient measurement. *World J Hepatol* 2015; **7**: 688-695 [PMID: 25866605 DOI: 10.4254/wjh.v7.i4.688]

99 **Moitinho E**, Escorsell A, Bandi JC, Salmerón JM, García-Pagán JC, Rodés J, Bosch J. Prognostic value of early measurements of portal pressure in acute variceal bleeding. *Gastroenterology* 1999; **117**: 626-631 [PMID: 10464138 DOI: 10.1016/S0016-5085(99)70455-5]

100 **Hernández-Gea V**, Berbel C, Baiges A, García-Pagán JC. Acute variceal bleeding: risk stratification and management (including TIPS). *Hepatol Int* 2018; **12**: 81-90 [PMID: 28634688 DOI: 10.1007/s12072-017-9804-3]

101 **Monescillo A**, Martínez-Lagares F, Ruiz-del-Arbol L, Sierra A, Guevara C, Jiménez E, Marrero JM, Buceta E, Sánchez J, Castellot A, Peñate M, Cruz A, Peña E. Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding. *Hepatology* 2004; **40**: 793-801 [PMID: 15382120 DOI: 10.1002/hep.20386]

102 **Anthony T**, Penta P, Todd RD, Sarosi GA, Nwariaku F, Rege RV. Rebleeding and survival after acute lower gastrointestinal bleeding. *Am J Surg* 2004; **188**: 485-490 [PMID: 15546555 DOI: 10.1016/j.amjsurg.2004.07.020]

103 **Ríos A**, Montoya MJ, Rodríguez JM, Serrano A, Molina J, Ramírez P, Parrilla P. Severe acute lower gastrointestinal bleeding: risk factors for morbidity and mortality. *Langenbecks Arch Surg* 2007; **392**: 165-171 [PMID: 17131153 DOI: 10.1007/s00423-006-0117-6]

104 **El Ouali S**, Barkun AN, Wyse J, Romagnuolo J, Sung JJ, Gralnek IM, Bardou M, Martel M. Is routine second-look endoscopy effective after endoscopic hemostasis in acute peptic ulcer bleeding? A meta-analysis. *Gastrointest Endosc* 2012; **76**: 283-292 [PMID: 22695209 DOI: 10.1016/j.gie.2012.04.441]

105 **Chiu PW**, Joeng HK, Choi CL, Tsoi KK, Kwong KH, Lam SH, Sung JJ. High-dose omeprazole infusion compared with scheduled second-look endoscopy for prevention of peptic ulcer rebleeding: a randomized controlled trial. *Endoscopy* 2016; **48**: 717-722 [PMID: 27275859 DOI: 10.1055/s-0042-107590]

106 **Kim SB**, Lee SH, Kim KO, Jang BI, Kim TN, Jeon SW, Kwon JG, Kim EY, Jung JT, Park KS, Cho KB, Kim ES, Kim HJ, Park CK, Park JB, Yang CH. Risk Factors Associated with Rebleeding in Patients with High Risk Peptic Ulcer Bleeding: Focusing on the Role of Second Look Endoscopy. *Dig Dis Sci* 2016; **61**: 517-522 [PMID: 26297133 DOI: 10.1007/s10620-015-3846-y]

107 **Cheng HC**, Wu CT, Chen WY, Yang EH, Chen PJ, Sheu BS. Risk factors determining the need for second-look endoscopy for peptic ulcer bleeding after endoscopic hemostasis and proton pump inhibitor infusion. *Endosc Int Open* 2016; **4**: E255-E262 [PMID: 27004241 DOI: 10.1055/s-0041-111499]

108 **Park SJ**, Park H, Lee YC, Choi CH, Jeon TJ, Park JC, Kim JH, Youn YH, Kim YJ, Kim JH, Lee KJ, Lim SG, Kim H, Bang BW. Effect of scheduled second-look endoscopy on peptic ulcer bleeding: a prospective randomized multicenter trial. *Gastrointest Endosc* 2018; **87**: 457-465 [PMID: 28735835 DOI: 10.1016/j.gie.2017.07.024]

109 **Chang MA**, Savides TJ. Endoscopic Management of Nonvariceal, Nonulcer Upper Gastrointestinal Bleeding. *Gastrointest Endosc Clin N Am* 2018; **28**: 291-306 [PMID: 29933776 DOI: 10.1016/j.giec.2018.02.003]

110 **Kovacs TO**, Jensen DM. Endoscopic therapy for severe ulcer bleeding. *Gastrointest Endosc Clin N Am* 2011; **21**: 681-696 [PMID: 21944418 DOI: 10.1016/j.giec.2011.07.012]

111 **Strate LL**, Naumann CR. The role of colonoscopy and radiological procedures in the management of acute lower intestinal bleeding. *Clin Gastroenterol Hepatol* 2010; **8**: 333-43; quiz e44 [PMID: 20036757 DOI: 10.1016/j.cgh.2009.12.017]

112 **Gralnek IM**, Neeman Z, Strate LL. Acute Lower Gastrointestinal Bleeding. *N Engl J Med* 2017; **376**: 1054-1063 [PMID: 28296600 DOI: 10.1056/NEJMcp1603455]

113 **Almadi MA**, Barkun AN. Patient Presentation, Risk Stratification, and Initial Management in Acute Lower Gastrointestinal Bleeding. *Gastrointest Endosc Clin N Am* 2018; **28**: 363-377 [PMID: 29933781 DOI: 10.1016/j.giec.2018.02.008]

**P-Reviewer:** Duvvuru NR, Kim BJ **S-Editor:** Wang JL **L-Editor: E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** South Korea

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

**Table 1 Causes of upper gastrointestinal bleeding**

|  |  |
| --- | --- |
| **Common causes** | **Other causes** |
| Peptic ulcer disease (gastric or duodenal) | Hemosuccus pancreaticus |
| Gastric or esophageal varices | Cameron lesions |
| Erosive esophagitis | Hemobilia |
| Upper gastrointestinal tumors | Aortoenteric fistula |
| Upper gastrointestinal angioectasias | Anastomotic bleeding |
| Mallory-Weiss tear | Arteriovenous malformation |
| Gastric or duodenal erosions | Acute esophageal necrosis |
| Dieulafoy lesion | Atrial-esophageal fistula |
|  | Gastric antral vascular ectasia |

Data from references[109,110].

**Table 2 Causes of acute small bowel and lower gastrointestinal bleeding by category**

|  |  |
| --- | --- |
| **Type** | **Causes** |
| Anatomic | Diverticulosis, including Meckel’s diverticulum |
| NSAID-induced enterocolopathy |
| Antiplatelet or anticoagulant-induced enterocolopathy |
| Stercoral ulceration (solitary rectal ulcer syndrome) |
| Anal fissure |
| Vascular | Ischemic colitis |
| Hemorrhoids |
| Angiodysplasias (Angioectasias) |
| Colorectal varices |
| Postpolypectomy bleeding |
| Radiation telangiectasia or proctitis |
| Dieulafoy’s lesion |
| Neoplastic | Colorectal polyps |
| Colorectal and anal cancers |
| Small bowel tumors, including gastrointestinal stromal tumor |
| Metastatic or direct invasion from other cancer |
| Inflammatory | Inflammatory bowel disease |
| Infectious colitis |

Data from references[111-113]. NSAID: Non-steroidal anti-inflammatory drug.

****

**Figure 1 Flowchart of assessment and management of patients with suspicious gastrointestinal bleeding.** GI: Gastrointestinal; EGD: Esophagogastroduodenoscopy; NSAIDs: Non-steroidal anti-inflammatory drugs; ICU: Intensive care unit; EVL: Endoscopic variceal ligation; UGIB: Upper gastrointestinal bleeding; LGIB: Lower gastrointestinal bleeding.